![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Abstract
CD38 is an ecto-enzyme that hydrolyzes NAD. Its expression is a prognostic marker for chronic lymphocytic leukemia. We have characterized individual variation in CD38 expression in lymphoblastoid cell lines from 288 healthy subjects of three ethnicities. Expression varied widely, with significant differences among ethnic groups, and was correlated significantly with CD38 enzymatic activity and protein levels. The CD38 gene was then resequenced using DNA from the same cell lines, with the identification of 53 single nucleotide polymorphisms (SNPs) and one indel, 39 novel. One SNP, rs1130169, was significantly associated with CD38 mRNA expression and explained a portion of the difference in expression among ethnic groups. EMS assay showed nuclear protein binding at or near this SNP. We also determined that variation in CD38 expression in these cell lines was associated with variation in antineoplastic drug sensitivity. These results represent a step toward understanding mechanisms involved in CD38 expression.
Declaration of interest: This work was supported, in part, by NIH Clinical Pharmacology Training Grant T32 GM08685 (W.R.H.), a Mayo Scholar Award (W.R.H.), the Big Award from the American Federation of Aging Research (AFAR) (E.N.C.), the Mayo Clinic CR20 Program (E.N.C.), and by NIH grants U01 GM61388 (The Pharmacogenetics Research Network) (L.L.P., I.M., K.K., M.L., R.M.W.), R01 GM28157 (R.M.W.), R01 CA132780 (R.M.W.), and a PhRMA Foundation ‘Center of Excellence in Clinical Pharmacology’ Award (R.M.W.).